234 related articles for article (PubMed ID: 36104566)
1. Brain-restricted mTOR inhibition with binary pharmacology.
Zhang Z; Fan Q; Luo X; Lou K; Weiss WA; Shokat KM
Nature; 2022 Sep; 609(7928):822-828. PubMed ID: 36104566
[TBL] [Abstract][Full Text] [Related]
2. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Fan Q; Aksoy O; Wong RA; Ilkhanizadeh S; Novotny CJ; Gustafson WC; Truong AY; Cayanan G; Simonds EF; Haas-Kogan D; Phillips JJ; Nicolaides T; Okaniwa M; Shokat KM; Weiss WA
Cancer Cell; 2017 Mar; 31(3):424-435. PubMed ID: 28292440
[TBL] [Abstract][Full Text] [Related]
3. Tissue-restricted inhibition of mTOR using chemical genetics.
Wassarman DR; Bankapalli K; Pallanck LJ; Shokat KM
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2204083119. PubMed ID: 36095197
[TBL] [Abstract][Full Text] [Related]
4. HMGA1 sensitizes esophageal squamous cell carcinoma to mTOR inhibitors through the ETS1-FKBP12 axis.
Guo JR; He KY; Yuan JL; An W; Yin WT; Li QT; Lu LY; Yang JY; Liu MJ; Li YJ; Zhao Y; Yang Q; Lei XY; Gao F; Zhang L; Wu DH; Li JQ; Zhao ZL; Liu H; Zhu LJ; Xiang XY; Sun QH; Jian YP; Xu ZX
Int J Biol Sci; 2024; 20(7):2640-2657. PubMed ID: 38725843
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
6. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
7. KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Venkata PP; Chen Y; Alejo S; He Y; Palacios BE; Loeffel I; Liu J; Pratap UP; Gray G; Achuthan Pillai SM; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Palakurthi S; Tekmal RR; Vadlamudi RK; Kost E; Sareddy GR
Cancer Lett; 2022 Jan; 524():219-231. PubMed ID: 34673129
[TBL] [Abstract][Full Text] [Related]
8. An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR.
Sekiguchi M; Kobashigawa Y; Kawasaki M; Yokochi M; Kiso T; Suzumura K; Mori K; Teramura T; Inagaki F
Protein Eng Des Sel; 2011 Nov; 24(11):811-7. PubMed ID: 21900305
[TBL] [Abstract][Full Text] [Related]
9. Multi-timescale dynamics study of FKBP12 along the rapamycin-mTOR binding coordinate.
Sapienza PJ; Mauldin RV; Lee AL
J Mol Biol; 2011 Jan; 405(2):378-94. PubMed ID: 21073880
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
11. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology of mTOR inhibition.
Guertin DA; Sabatini DM
Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975
[TBL] [Abstract][Full Text] [Related]
13. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
[TBL] [Abstract][Full Text] [Related]
14. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
15. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
[TBL] [Abstract][Full Text] [Related]
16. The role of glycerol-water mixtures in the stability of FKBP12-rapalog-FRB complexes.
Lopez JJD; Gaza JT; Nellas RB
J Mol Graph Model; 2023 Nov; 124():108556. PubMed ID: 37423019
[TBL] [Abstract][Full Text] [Related]
17. mTOR kinase structure, mechanism and regulation.
Yang H; Rudge DG; Koos JD; Vaidialingam B; Yang HJ; Pavletich NP
Nature; 2013 May; 497(7448):217-23. PubMed ID: 23636326
[TBL] [Abstract][Full Text] [Related]
18. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting 4EBP1 in Glioblastoma.
Fan QW; Nicolaides TP; Weiss WA
Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243
[TBL] [Abstract][Full Text] [Related]
20. In smooth muscle, FK506-binding protein modulates IP3 receptor-evoked Ca2+ release by mTOR and calcineurin.
MacMillan D; Currie S; Bradley KN; Muir TC; McCarron JG
J Cell Sci; 2005 Dec; 118(Pt 23):5443-51. PubMed ID: 16278292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
